By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Daiichi Sankyo Company, Ltd. 

3-5-1, Nihonbashi-honcho

Chuo-ku  Tokyo  103-8426  Japan
Phone: +81-3-6225-1111 Fax:


SEARCH JOBS

Daiichi Sankyo is focused on the discovery and development of novel oncology agents with the goal of delivering first-in-class and best-in-class treatments that address unmet medical needs. The oncology pipeline of Daiichi Sankyo continues to grow and currently includes both small molecules and monoclonal antibodies with novel targets in both solid and hematological cancers.

YEAR FOUNDED:

1899

LEADERSHIP:

CEO: Joji Nakayama

CLINICAL TRIAL:

Please click here for clinical trial information.

PRODUCTS:

All Products


Key Statistics


Email:
Ownership: Private

Web Site: Daiichi Sankyo
Employees:
Symbol: 
 



Industry
Pharmaceutical






Company News
Daiichi Sankyo Announces 15 Billion Yen Manufacturing Investment To Support Acceleration Of Antibody Drug Conjugate Portfolio 4/27/2017 7:45:15 AM
Heptares Enters Agreement With Daiichi Sankyo To Discover And Develop Novel, Small-Molecules For The Treatment Of Pain 3/13/2017 6:47:57 AM
Daiichi Sankyo Initiates ENTRUST-AF PCI Study Investigating Once-Daily SAVAYSA (Edoxaban) In Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention With Stenting 3/6/2017 6:28:23 AM
ArQule (ARQL), Daiichi Sankyo's Liver Cancer Drug Comes Up Short in Another Phase III Study 2/17/2017 6:21:54 AM
Daiichi Sankyo Shutters Yet Another R&D Facility 2/10/2017 6:22:46 AM
Charleston Laboratories And Daiichi Sankyo Receive Complete Response Letter From FDA For New Drug Application For CL-108 (Hydrocodone, Acetaminophen, Promethazine) Tablets For Oral Use 2/3/2017 11:23:16 AM
Daiichi Sankyo Release: Company Initiates Phase 1/2 Study Of Novel Antibody Drug Conjugate U3-1402 In Patients With HER3-Positive Metastatic Or Unresectable Breast Cancer 1/18/2017 8:42:50 AM
Daiichi Sankyo to Shutter Indian R&D Center, 170 Employees Affected 1/11/2017 6:12:41 AM
Daiichi Sankyo And DarwinHealth Announce Strategic Partnership To Deploy A Quantitative Systems Biology Discovery Platform To Prioritize Daiichi Sankyo Cancer Enterprise Compounds For Development 12/13/2016 6:32:47 AM
Daiichi Sankyo Presents Phase 1 Data For MDM2 Inhibitor DS-3032 In Acute Myeloid Leukemia And Myelodysplastic Syndrome At The 58th Annual Meeting Of The American Society of Hematology 12/5/2016 9:50:53 AM
123456
//-->